XSHG
605199
Market cap348mUSD
Oct 09, Last price
5.81CNY
1D
-0.34%
1Q
0.35%
IPO
-29.32%
Name
Hainan Huluwa Pharmaceutical Group Co Ltd
Chart & performance
P/E
—
P/S
2.58
EPS
—
Div yield, %
2.14%
Shrs. gr., 5y
1.00%
Rev. gr., 5y
-4.96%
Revenues
901m
-36.27%
Net income
-287m
L+4.71%
CFO
137m
P
Dividend
Jul 16, 20240.125 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Haikou, China.
Key people
Jingping Liu
Chairman of the Board, General Manager · since 2025
Peihu Li
Deputy General Manager · since 2016
Quanguo Liu
Deputy General Manager · since 2025
Ping Liu
Deputy General Manager · since 2025
Tianbao Wei
Deputy General Manager · since 2016
Junling Li
Deputy General Manager, Director · since 2019
Qibo Tang
Director
Qingtao Wang
Secretary of the Board, Director · since 2025
Hui Yu
Chief Financial Officer, Deputy General Manager, Director · since 2023
Hui Lin
Independent Director · since 2025
Shixian Wang
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||